Table 4

Cardiac MPO and plasma CPK activities measured in rats subjected to 30 min of coronary artery occlusion followed by 120 min of reperfusion

Group	Cardiac MPO		Plasma CPK
Group	Area Not at Risk	Area at Risk	0 min (Pre-Occlusion)	30 min (End-Occlusion)	150 min (End-Reperfusion)
	U/g tissue		U/l
Sham (n = 14)	0.37 ± 0.03		236 ± 17	258 ± 18	282 ± 17
Vehicle ⁺ MI/R (n = 19)	0.41 ± 0.03	4.27 ± 0.39	245 ± 13	846 ± 29	1837 ± 90
NCX 10 ⁺MI/R (n = 13)	0.40 ± 0.03	3.52 ± 0.33	230 ± 19	742 ± 41	1696 ± 81
NCX 30 ⁺ MI/R (n= 13)	0.42 ± 0.06	1.97 ± 0.22^4-165	253 ± 23	575 ± 38^4-165	1231 ± 72^4-165
NCX 100 ⁺ MI/R (n = 14)	0.38 ± 0.04	1.01 ± 0.10^4-165	228 ± 18	347 ± 32^4-165	593 ± 33^4-165
ASA 54 ⁺ MI/R (n = 14)	0.40 ± 0.04	3.09 ± 0.41^4-150	252 ± 18	684 ± 57^4-150	1464 ± 83^4-150

Vehicle (2 ml/kg PEG 400), NCX 4016 (NCX; 10, 30, and 100 mg/kg) and ASA were (50 mg/kg) were administered orally for 5 consecutive days. Data are expressed as mean ± S.E. In parentheses, number of experiments. Sham-operated animals were treated with vehicle.

↵4-150 P < 0.05,
↵4-165 P < 0.001 versus vehicle + MI/R group.